LPCN
$7.67
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprisi...
Recent News
Lipocine: Q4 Earnings Snapshot
The Salt Lake City-based company said it had a loss of 34 cents per share. The specialty pharmaceutical company posted revenue of $1.1 million in the period. For the year, the company reported a loss of $9.6 million, or $1.69 per share.
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.51% and -52.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15
We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 21, H.C. Wainwright raised its price target on Lipocine Inc. (NASDAQ:LPCN) to $15 from $7 and maintained a Buy rating on the shares, citing the favorable safety profile observed for LPCN 1154. The firm sees the program as a […]
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Lipocine (LPCN) delivered earnings and revenue surprises of -5.36% and +15.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?